Merck Arcoxia At ACR: Data Suggest Thrombotic Profile Similar To Vioxx
Executive Summary
Merck's Arcoxia (etoricoxib) does not interfere with the platelet aggregation effects of low-dose aspirin, according to an abstract presented at the American College of Rheumatology annual scientific meeting Nov. 11-15 in San Francisco
You may also be interested in...
Merck COX-2 Cardiovascular Safety Studies Will Enroll 30,000 Subjects
Merck plans to enroll approximately 30,000 subjects in cardiovascular safety trials to resolve issues raised about the CV effects of its COX-2 inhibitors Vioxx (rofecoxib) and Arcoxia (etoricoxib)
Merck COX-2 Cardiovascular Safety Studies Will Enroll 30,000 Subjects
Merck plans to enroll approximately 30,000 subjects in cardiovascular safety trials to resolve issues raised about the CV effects of its COX-2 inhibitors Vioxx (rofecoxib) and Arcoxia (etoricoxib)
Medicare Rx Benefit Could Help Ignite COX-2 Market – Pharmacia’s Hassan
A Medicare drug benefit could help jump-start the stalled COX-2 inhibitor market, Pharmacia CEO Fred Hassan told analysts during the company's annual investor day in New York City Nov. 28